Voyager Therapeutics

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Voyager Therapeutics excels in 2022, poised for CNS therapeutic breakthroughs

Voyager Therapeutics demonstrated strong performance in 2022, leveraging key partnerships and advancements in their pipeline programs to drive innovation and growth in the CNS therapeutics space.
While facing challenges in operational clarity and regulatory hurdles, the company's scientific strengths and financial stability position it well to capitalize on opportunities for expanding collaborations and advancing novel therapeutic approaches.
With a focus on CNS delivery, tissue targeting, and surrogate markers, Voyager is poised to make significant strides in addressing neurological disorders and enhancing treatment efficacy, offering potential value for investors and patients alike.

Voyager Therapeutics reports strong Q1 earnings and strategic advancements

Voyager Therapeutics showcased robust financial performance and strategic advancements in neurotherapeutics and gene therapy, positioning the company for future growth.
While facing challenges related to animal model predictability and reimbursement considerations, Voyager is actively leveraging strengths in diversified therapeutic approaches and strategic partnerships.
Opportunities lie in exploring synergistic treatments, proactive risk mitigation, and innovative therapeutic strategies to address complex neurological disorders effectively.
Overall, Voyager's focus on innovation, strategic partnerships, and comprehensive drug development approaches underscores its commitment to advancing treatments for neurological diseases.

Voyager Therapeutics excels in Q2, poised for neurogenetic medicine expansion

Voyager Therapeutics demonstrated strong financial health, innovative advancements in CNS programs, and strategic partnerships driving revenue growth. While facing challenges in R&D management and program milestones, the company's opportunities lie in upcoming milestones and expansion in neurogenetic medicine.

Voyager Therapeutics advances CNS gene therapy with strong partnerships and cash balance

Voyager Therapeutics is making strides in CNS gene therapy delivery with strong financial backing
Facing challenges in toxicology studies and patient recruitment while eyeing collaboration opportunities
Opportunities lie in biomarker utilization, partnership models, and advancing key programs towards clinical milestones

Voyager Therapeutics reports robust earnings and advances in neurogenetic therapies

Voyager Therapeutics showcased a strong financial performance, progress in their pipeline programs, and a focus on innovation and differentiation in the gene therapy space.
While facing competition and regulatory challenges, the company's strategic strengths, collaborations, and positive data present opportunities for future growth and impact.
Analysts' inquiries into program progress and regulatory timelines underscore investor interest in Voyager's development trajectory and the potential of their neurogenetic therapies.
With a robust financial position, promising pipeline advancements, and a commitment to unique approaches, Voyager is poised to make significant strides in the treatment of neurological disorders.

Voyager Therapeutics excels in Q1, eyes Alzheimer's breakthroughs

Voyager Therapeutics demonstrated strong financial performance and pipeline advancements in Q1 2024.
The company's focus on neurogenetic medicine and innovative gene therapy programs is a key strength.
Challenges include demonstrating efficacy in ALS therapy and optimizing brain delivery methods.
Opportunities lie in exploring novel treatment approaches and anticipating key data releases.

Voyager Therapeutics excels in Q2 with innovative pipeline advancements

Voyager Therapeutics demonstrated strong performance in Q2 2024, focusing on key milestones, tau-directed programs, and derisking strategies.
While facing challenges in program optimization and competitive positioning, the company's strengths lie in innovative pipeline advancements and financial stability.
Opportunities for multi-organ specificity, disease-specific programs, and treatment refinement position Voyager for continued growth and therapeutic innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q3 2024 Results Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer and Chief of Staff to the CEO Alfred Sandrock - President and Chief Executive Officer Toby Ferguson - Chief Medical Officer Todd Carter - Chief Scientific Officer Nathan Jorgensen - Chief Financial Officer Conference Call Participants Phil Nadeau - TD Cowen Jack Allen - Robert W. Baird Joon Lee - Truist Securities Jay Olson - Oppenheimer & Co. Lili Nsongo - Leerink Partners Patrick Trucchio - HC Wainwright Operator Good afternoon, and welcome to the Voyager Therapeutics Third Quarter 2024 Financial Results Conference Call.

Voyager Therapeutics, Inc. (VYGR) Q3 2024 Earnings Call Transcript

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.59 per share a year ago.

Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates

- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 -

Voyager Reports Third Quarter 2024 Financial and Operating Results

LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences:

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November 12, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET.

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

Voyager Therapeutics (VYGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength?

LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant to such employee of a non-qualified stock option and restricted stock units as an inducement material to such employee's entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager's Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option award became effective on August 28, 2024, and the restricted stock unit award is scheduled to become effective on October 1, 2024.

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Voyager Therapeutics, Inc. initial safety and PK data from the phase 1a study using VY7523 for the treatment of patients with Alzheimer's Disease expected 1st half of 2025. Targeting the C-terminal for AD patients instead of N-terminal domain could end up resulting in a significantly greater reduction of tau protein. The global Alzheimer's Disease Therapeutics market is expected to reach $30.8 billion by 2033.

Voyager: Anti-Tau Antibody Differentiation For AD Treatment Could Boost Prospects

Allogene Therapeutics Inc

Blueprint Medicines

CRISPR Therapeutics

Precision Biosciences

REGENXBIO

Sarepta Therapeutics

With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.

7 Biotech Stocks to Buy for Their Game-Changing Potential

Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer Alfred Sandrock - Chief Executive Officer Toby Ferguson - Chief Medical Officer Nathan Jorgensen - Chief Financial Officer Todd Carter - Chief Scientific Officer Conference Call Participants Jack Allen - Robert W. Baird & Co. Divya Rao - TD Cowen Ry Forseth - Guggenheim Securities Mehdi Goudarzi - Truist Securities Sumant Kulkarni - Canaccord Genuity Kuan-Hung Lin - Wells Fargo Securities Laura Chico - Wedbush Securities Operator Good afternoon, and welcome to the Voyager Therapeutics Second Quarter 2024 Financial Results Conference Call.

Voyager Therapeutics, Inc. (VYGR) Q2 2024 Earnings Call Transcript

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase on August 14, 2024, at 9:30 a.m. ET.

Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.51 per share a year ago.

Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates

- Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer's disease -

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024, at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024, at 7:00 a.m. ET.

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc.

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

Alnylam Pharmaceuticals

Clover Health Investments

Enovix Corporation

General American Investors

Halliburton

Logistic Properties Of The Americas

Adams Natural Resources Fund Inc

POET Technologies Inc

Roivant Sciences Ltd

Uranium Royalty Corp

The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, and Haliburton. Many of the ideas included have not been discussed in months on the site. One of the ideas is actually first-ever coverage for this ticker.

The 'Undercovered' Dozen From June 1-6

Voyager Therapeutics, Inc. is a biotech company focused on developing gene-based therapies for neurological conditions. The company has made progress in its pipeline, including the start of the Phase 1 clinical trial for VY-TAU01, its Alzheimer's disease candidate. Voyager's strong revenue-driver partnerships and financial stability make it a "Strong Buy" for long-term investors.

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Aurinia Pharmaceuticals

Amicus Therapeutics

Today, we take a look at three promising biotech names that currently trade under $10 a share. Two of these are quickly moving towards profitability, and the other is cash rich and has several partnerships with large pharma companies. We profile all three of these names with favorable risk/reward profiles in the paragraphs below.

3 Biotech Names Under $10 I Own

LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigational anti-tau antibody developed to inhibit the spread of pathological tau in Alzheimer's disease.

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's Disease

Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer Alfred Sandrock - CEO Todd Carter - Chief Scientific Officer Toby Ferguson - Chief Medical Officer Robin Swartz - COO and Principal Financial Officer Conference Call Participants Mehdi Goudarzi - Truist Securities Jack Allen - Baird Patrick Trucchio - H.C. Wainwright & Co. Philip Nadeau - TD Cowen Ry Forseth - Guggenheim Securities David Hoang - Citigroup Sumant Kulkarni - Canaccord Genuity Yanan Zhu - Wells Fargo Securities Laura Chico - Wedbush Joon Lee - Truist Securities Operator Good afternoon, and welcome to Voyager Therapeutics First Quarter 2024 Financial Results Conference Call.

Voyager Therapeutics, Inc. (VYGR) Q1 2024 Earnings Call Transcript

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to earnings of $2.94 per share a year ago.

Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates

- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer's disease; expect to begin single ascending dose trial in the coming weeks -

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding -

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report first quarter 2024 financial and operating results after market close on Monday, May 13, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results.

News for Voyager Therapeutics Stock (VYGR)